Edition:
India

Agenus Inc (AGEN.OQ)

AGEN.OQ on NASDAQ Stock Exchange Capital Market

5.06USD
23 Feb 2018
Change (% chg)

$0.21 (+4.33%)
Prev Close
$4.85
Open
$4.84
Day's High
$5.08
Day's Low
$4.84
Volume
451,526
Avg. Vol
331,033
52-wk High
$5.44
52-wk Low
$3.20

Select another date:

Thu, Jan 25 2018

BRIEF-Agenus Inc Files For Sale Of Up 10 Mln Shares Of Common Stock By Selling Stockholders

* AGENUS INC FILES FOR SALE OF UP 10 MILLION SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING Source text (http://bit.ly/2n84why) Further company coverage:

BRIEF-Agenus Announces Combination Clinical Trials Of Anti-CTLA4 & Anti-PD1

* AGENUS ANNOUNCES COMBINATION CLINICAL TRIALS OF ITS ANTI-CTLA4 (AGEN1884) & ANTI-PD1 (AGEN2034)

BRIEF-Agenus Announces $230 Mln Royalty Monetization With Healthcare Royalty Partners

* AGENUS INC. ANNOUNCES $230 MILLION ROYALTY MONETIZATION WITH HEALTHCARE ROYALTY PARTNERS

BRIEF-Agenus reports Q3 loss per share $0.37

* Agenus reports third quarter 2017 financial results and provides corporate update

BRIEF-Agenus files for mixed shelf of up to $250 million

* Agenus Inc files for mixed shelf of up to $250 million – SEC filing‍​ Source text - (http://bit.ly/2yzul1n) Further company coverage:

UPDATE 2-'Impressed' FDA panel unanimously recommends GSK shingles vaccine

Sept 13 A U.S. Food and Drug Administration advisory panel on Wednesday voted 11-0 that the safety and efficacy of GlaxoSmithKline's Shingrix shingles vaccine warrants approval for its use in adults aged 50 and over.

Select another date: